Dietary Supplements in Poland: Legal and Regulatory Guide for Foreign Companies

Dietary supplements Poland market entry looks deceptively simple from the outside: file a notification, print a Polish label, start shipping. The real challenge lies in navigating Główny Inspektorat Sanitarny (GIS) product classification, EU Food Business Operator (FBO) mandates, and strict labelling compliance. The wrong regulatory route rarely fails on day one—it fails months later, during a GIS explanatory audit, when product blockages and recall orders dismantle distribution.

Foreign manufacturers, brand owners, and distributors are stepping into a system built on a single, easily misunderstood principle—the presumption of compliance. GIS does not “approve” a supplement before it goes to market, but it retains full authority to review the product afterward. A poorly prepared notification file, an unregistered EU responsible entity, or a borderline ingredient can trigger an explanatory proceeding that halts sales long after launch.

This guide sets out the regulatory framework, classification risks, entity structuring options, and compliance obligations that foreign dietary supplement companies need to address before—not after—entering the Polish market.

Table of Contents

• Regulatory Framework: How Food Supplements Are Governed in Poland
• Product Classification: Dietary Supplement vs. Medicinal Product vs. Medical Device
• Market Entry for Foreign Companies: Entity Setup and EU FBO Rules
• The GIS Notification Process: How to Register Supplements in Poland
• Mandatory Labelling and Packaging Requirements in Polish
• Advertising and Marketing Restrictions for Dietary Supplements
• Sanitary Premises Registration and HACCP Compliance
• Common Pitfalls for Foreign Supplement Brands Entering Poland
• How CGO Legal Supports Foreign Life Sciences Companies
• Frequently Asked Questions (FAQ)
• Explore the Life Sciences & Healthcare Cluster

Regulatory Framework: How Food Supplements Are Governed in Poland

Dietary supplements in Poland are regulated as a category of food, not medicine, but the framework governing them draws on both Polish and EU law simultaneously.

At the national level, the core statute is the Act on Food Safety and Nutrition (Ustawa o bezpieczeństwie żywności i żywienia) of 25 August 2006 (consolidated text: Journal of Laws / Dz.U. 2023, item 1448, as amended). Article 29 of this Act sets out the notification obligation, and Article 3 defines a dietary supplement (środek spożywczy) as a foodstuff intended to supplement a normal diet, rather than a medicinal product.

At the EU level, three instruments shape the compliance perimeter:

• Directive 2002/46/EC on the approximation of the laws of Member States relating to food supplements, which harmonizes the definition of “food supplement” and the permitted vitamin and mineral sources across the EU.
• Regulation (EU) No 1169/2011 on the provision of food information to consumers, which requires that a Food Business Operator (FBO) established within the EU be identifiable on the label as the party responsible for the information provided.
• Regulation (EC) No 1924/2006 on nutrition and health claims made on foods, which restricts which claims can lawfully appear on packaging and in marketing materials.

Two authorities matter most in day-to-day compliance work:

• The Chief Sanitary Inspectorate (Główny Inspektorat Sanitarny, GIS) is the central body responsible for receiving notifications of dietary supplements placed on the Polish market for the first time, and for supervising their composition, labelling, and safety on an ongoing basis.
• The State Sanitary Inspection (Państwowa Inspekcja Sanitarna, PIS), acting through its local branches, supervises storage conditions, hygiene, and the sanitary registration of premises used by importers and distributors.

Under Polish law, a notified product is generally free to enter the market once GIS has issued an Official Confirmation of Receipt (Urzędowe Poświadczenie Odbioru, UPO)—but that confirmation is procedural, not a safety or compliance approval. GIS retains the right to open an explanatory proceeding at any point afterward, a distinction that foreign companies frequently underestimate.

Note for 2026: a legislative amendment to the Act on Food Safety and Nutrition has been under parliamentary review, proposing tighter notification wording under Article 29, a stronger evidentiary basis for the notified product’s status, and substantially higher financial penalties for advertising and labelling violations. The exact scope and effective date should be verified against the current legislative calendar before relying on it in a specific case.

Product Classification: Dietary Supplement vs. Medicinal Product vs. Medical Device

The single most consequential legal question for a new product is not “how do we notify it”—it is “what is it.” Polish and EU authorities classify a product by its composition, presentation, and pharmacological action, not by the label the manufacturer chooses to apply.

A dietary supplement is legally a foodstuff: a concentrated source of vitamins, minerals, or other substances with a nutritional or physiological effect, marketed in dose form (capsules, tablets, sachets, ampoules) and intended to supplement, not replace, the normal diet. Once a product’s composition or claimed function crosses into disease prevention, treatment, or a defined pharmacological, immunological, or metabolic action, it risks reclassification as a medicinal product, placing it under the jurisdiction of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, URPL) rather than GIS.

This grey area—commonly referred to as borderline products—is where a significant share of GIS explanatory proceedings originate. A supplement formulated with high-dose active substances, presented with disease-related claims, or resembling a pharmaceutical dosage form can be challenged by either GIS or URPL, generally on a case-by-case basis, with no guarantee that a product notified successfully in another EU state will be treated the same way in Poland.

Companies planning to launch products with pharmacologically active botanicals, high-potency vitamin/mineral doses, or health-adjacent claims should generally commission a composition and claims audit before filing any GIS notification, since correcting a misclassified product after the fact is materially more disruptive than resolving it before submission.

Market Entry for Foreign Companies: Entity Setup and EU FBO Rules

Foreign companies approach the Polish market from two structurally different starting points, and the difference matters at every later stage of compliance.

Companies Already Established Within the EU

Companies already established within the EU can generally rely on their existing EU entity as the Food Business Operator for Polish notification purposes, provided the entity accepts responsibility for the label information under Regulation (EU) 1169/2011. Cross-border trade within the single market does not remove the obligation to notify GIS before first placing the product on the Polish market—a notification made in another member state does not automatically extend to Poland.

Companies Established Outside the EU

Companies established outside the EU (United States, United Kingdom, and Asian markets in particular) face a stricter requirement. Regulation (EU) 1169/2011 requires the Food Business Operator identified on the label to be established within the European Union. A non-EU company cannot notify GIS or place a product on the Polish market directly under its own foreign entity; it must instead operate through one of the following routes:

• Incorporating a Polish limited liability company (spółka z ograniczoną odpowiedzialnością, Sp. z o.o.), which then acts as the EU-based FBO and Polish taxpayer of record.
• Opening a branch (oddział) of the foreign parent company in Poland, allowing the parent to trade under its own name through a locally registered establishment.
• Contracting a local importer or distributor who is already established in the EU and willing to assume FBO responsibility for the product—generally the fastest route to market, though it transfers a degree of regulatory control to the local partner.

Each route carries different tax, liability, and control trade-offs, and the right choice generally depends on sales volume projections, the number of SKUs, and how much operational control the foreign brand wants to retain over labelling, notification timing, and future explanatory proceedings.

Once an entity route is selected, company formation and VAT registration become the next practical steps. Our guides on company registration in Poland and VAT registration in Poland cover the formation and tax mechanics in detail.

The GIS Notification Process: How to Register Supplements in Poland

Before a dietary supplement is placed on the Polish market for the first time, the responsible entity must submit an electronic notification to GIS through the Electronic Notification System (Elektroniczny System Powiadomień), under Article 29 of the Act on Food Safety and Nutrition. The notification includes the product’s Polish-language label, composition, and—where the product is already marketed in another EU member state—a reference to the competent authority and prior notification in that state.

Poland operates on a presumption of compliance: once the notification is submitted and an Official Confirmation of Receipt (UPO) is issued, the product can generally be placed on the market without waiting for a substantive review. This is often misread by foreign entrants as a form of pre-market approval. It is not. GIS retains the authority to open an explanatory proceeding (postępowanie wyjaśniające) at any point after the notification, typically triggered by composition concerns, a competitor complaint, a market surveillance sample, or an inconsistency between the notified formula and the product actually sold.

An explanatory proceeding can result in requests for additional documentation, a formal opinion from the GIS Dietary Supplements Team (Zespół do spraw Suplementów Diety) on contested ingredients, and—where non-compliance is found—an order restricting or withdrawing the product from the market. Because this process typically unfolds months after launch, companies that treat the notification as a one-time filing rather than an ongoing compliance obligation are the ones most exposed to disruption.

For the step-by-step notification workflow, required annexes, and translation requirements, see our detailed guide on GIS notification steps.

Mandatory Labelling and Packaging Requirements in Polish

Polish labelling requirements combine the general EU food information rules with Poland-specific formatting expectations, and GIS reviews both the notified label and the label actually printed on the product sold in stores.

At minimum, the Polish-language label must generally include:

• The qualitative and quantitative composition, listing active substances and their amounts per recommended daily portion.
• The Reference Intake / RWS (Referencyjna Wartość Spożycia) for vitamins and minerals, expressed as a percentage where applicable.
• The recommended daily portion and an explicit warning not to exceed it.
• Standard supplement warnings, including that the product is not a substitute for a varied diet and should be kept out of reach of young children.
• The name and EU address of the Food Business Operator responsible for the product information, consistent with Regulation (EU) 1169/2011.

Nutrition and health claims are governed separately under Regulation (EC) 1924/2006, which restricts claims to those authorized on the EU register and prohibits claims attributing disease-prevention or treatment properties to a product classified as a food. A claim that is lawful in the country of manufacture is not automatically lawful in Poland if it falls outside the authorized EU claims list or implies a medicinal function.

A literal translation of an existing label is rarely sufficient. Vitamin and mineral upper limits, permitted botanical ingredients, and claim wording are generally subject to Polish-specific review, and a label audit before printing is the more efficient way to avoid a relabelling exercise after a GIS query. For a full breakdown of formatting rules and claim restrictions, see our guide on Polish supplement labelling standards.

Advertising and Marketing Restrictions for Dietary Supplements

Marketing a dietary supplement in Poland sits under the joint oversight of GIS and the Office of Competition and Consumer Protection (Urząd Ochrony Konkurencji i Konsumentów, UOKiK), the latter acting primarily on unfair commercial practices and misleading advertising.

Under the Act on Food Safety and Nutrition and general consumer protection law, dietary supplement advertising generally may not:

• Attribute to the product properties of preventing or treating disease, which would misrepresent it as a medicinal product.
• Suggest that a balanced, varied diet cannot provide adequate nutrients without the product.
• Use the image, voice, or endorsement of a doctor or pharmacist, or otherwise imply a medical authority behind the product, a practice specifically restricted in the Polish market.
• Mislead as to the product’s characteristics, effects, or composition.

Enforcement in this area has intensified, and legislative proposals under review would increase financial penalties tied to advertising violations. Advertising campaigns—including influencer and social media content—should generally be reviewed against these restrictions before launch, since a non-compliant campaign can itself become the trigger for a GIS explanatory proceeding on the underlying product. For the detailed advertising rulebook, see our guide on supplement advertising regulations in Poland.

Sanitary Premises Registration and HACCP Compliance

Beyond the product notification, any entity storing, importing, or distributing dietary supplements in Poland is generally required to register its premises with the relevant Poviat Sanitary-Epidemiological Station (Powiatowa Stacja Sanitarno-Epidemiologiczna, PSSE), the local branch of the State Sanitary Inspection responsible for hygiene and storage oversight.

Registered premises are expected to operate under HACCP (Hazard Analysis and Critical Control Points) principles, covering storage temperature and humidity control, pest management, batch traceability, and staff hygiene procedures. For importers and distributors that do not manufacture the product themselves, HACCP obligations are generally scaled to the storage and handling risk involved, but registration itself is not optional, and PSSE inspections can occur independently of any GIS notification review.

Foreign companies contracting a third-party logistics provider in Poland should confirm that the provider’s premises are already PSSE-registered and HACCP-compliant, since responsibility for the product’s condition on the Polish market is not automatically transferred away from the notifying entity.

Common Pitfalls for Foreign Supplement Brands Entering Poland

The same compliance gaps appear repeatedly in foreign market entry files. These are the ones most likely to surface during or after a GIS explanatory proceeding:

• Assuming an EU notification is portable. A notification filed with the competent authority of another EU member state does not substitute for a Polish GIS notification. Each first placement on the Polish market requires its own filing, referencing the prior notification rather than replacing it.
• Launching without an EU-based FBO. Non-EU companies that ship directly under their own foreign entity, without a Polish subsidiary, branch, or EU-based distributor accepting FBO responsibility, are not compliant with Regulation (EU) 1169/2011—regardless of how the product is labelled.
• Translating the label instead of auditing it. A word-for-word translation of a foreign label frequently fails on Polish-specific points: vitamin and mineral dosage limits, permitted botanical ingredients, and the authorized EU claims list. Translation is a language exercise; compliance is a legal one.
• Treating the UPO as a market approval. Receiving the Official Confirmation of Receipt confirms the filing was submitted—it does not confirm GIS has reviewed or approved the composition. Explanatory proceedings can be opened well after the product is already on shelves.
• Underestimating advertising exposure. Marketing language that would be unremarkable in another jurisdiction—implying disease prevention, using medical endorsements—can trigger scrutiny in Poland independently of the underlying product notification.

How CGO Legal Supports Foreign Life Sciences Companies

Our Regulatory & Corporate practice supports foreign dietary supplement manufacturers, brand owners, and distributors through the full market entry lifecycle in Poland. The work typically spans several workstreams that run in parallel rather than sequentially, since entity structuring, notification preparation, and label review interact with each other at several points.

On the regulatory side, we handle Composition and label qualification audits (assessing borderline product risk before notification), GIS notification handling (including preparation and filing of the electronic notification and supporting documentation), and representation in explanatory proceedings, including responses to GIS information requests and, where relevant, coordination with URPL on classification disputes.

On the corporate side, we cover entity structuring and incorporation—including Sp. z o.o. formation, branch registration, and FBO designation—as well as tax and contractual advisory covering VAT registration, distribution agreements, and cross-border supply arrangements.

Frequently Asked Questions (FAQ)

Written by the Regulatory & Corporate Law Practice Team at CGO Legal | Last updated: July 2026

This article provides general information on the Polish regulatory framework for dietary supplements and does not constitute legal advice. Classification, notification, and labelling outcomes are assessed on a case-by-case basis; foreign companies should seek dedicated legal review before launching a specific product in Poland.